The influence of hormone therapy with drospirenone-estradiol on endometrioid type endometrial cancer patients
- 주제(키워드) Endometrial Neoplasms , Hormone Replacement Therapy , Drospirenone , Estradiol
- 주제(기타) Oncology; Obstetrics & Gynecology
- 설명문(일반) [Lim, Soyi; Lee, Kwang-Beom] Gachon Univ, Coll Med, Dept Obstet & Gynecol, Gil Med Ctr, 21 Namdong Daero 774 Beon Gil, Incheon, South Korea; [Kim, Yun Hwan] Ewha Womans Univ, Coll Med, Mokdong Hosp, Dept Obstet & Gynecol, Seoul, South Korea; [Lee, Jong-Min] Kyung Hee Univ, Sch Med, Kyung Hee Univ Hosp Gangdong, Dept Obstet & Gynecol, Seoul, South Korea
- 등재 SCIE, SCOPUS, KCI등재
- 발행기관 KOREAN SOC GYNECOLOGY ONCOLOGY & COLPOSCOPY
- 발행년도 2018
- URI http://www.dcollection.net/handler/ewha/000000156641
- 본문언어 영어
- Published As http://dx.doi.org/10.3802/jgo.2018.29.e72
초록/요약
Objective: To determine whether drospirenone/estradiol (DRSP/E2) has an adverse effect on clinical outcomes in surgically staged International Federation of Gynecology and Obstetrics (FIGO) stage I/II endometrial cancer (EC) patients. Methods: In a retrospective case-controlled study, 58 women with EC who had received DRSP/E2 postoperatively were compared with 116 women who had not. And, oncologic safety of postoperative hormone therapy with DRSP/E2 in EC survivors were compared between the 2 groups after propensity score matching using a logistic regression model. Results: The median ages were 47.7 years and 53.6 years for the study and the control groups, respectively (p<0.001). The study group had similar parity (p=0.71), lower body mass index (p=0.03) and more premenopausal women (p<0.001) than the control group. The stages were completely matched. The grades (p=0.42), lymphovascular space invasion (p=0.23), preoperative cancer antigen 125 (CA125) level (p=0.89), and hormone receptor status (p=0.07) were similar in both groups. The median tumor diameter was statistically larger in the study group than in the control group (p<0.001). Both group received similar adjuvant therapy (p=0.80). In the propensity matching, only hormone receptor status was significantly different (p=0.03). In the univariate analysis, only stage was significantly associated with disease-free survival (DFS) and there was no variable associated with overall survival (OS). And, there was no significant factor identified in multivariate analysis. The difference in the DFS (p=0.63) and in the OS (p=0.32) was not significant. The same results were obtained after propensity score matching. Conclusion: Postoperative hormone therapy with DRSP/E2 in EC survivors did not increase recurrence or the death rate.
more